Current Status as of May 25, 2026
LOY-002 is not available for prescription yet. It is still moving through the FDA Center for Veterinary Medicine’s expanded conditional approval pathway.
The meaningful update is that Loyal has publicly reported completion of two major technical sections:
- Reasonable Expectation of Effectiveness (RXE): accepted in February 2025.
- Target Animal Safety (TAS): accepted in January 2026.
The remaining major technical section is Chemistry, Manufacturing, and Controls (CMC). That section is about whether the drug can be manufactured consistently and safely at commercial quality. Until CMC is accepted and FDA grants conditional approval, owners cannot get LOY-002 through a veterinarian.
For the broader pipeline, see the LOY-001 and LOY-002 FDA progress hub and FDA regulation of dog longevity drugs.
What LOY-002 Is
LOY-002 is Loyal’s senior dog longevity drug candidate. Loyal describes it as a daily pill intended to support healthy aging in senior dogs by targeting age-associated metabolic dysfunction.
That makes it different from:
- LOY-001: a large and giant dog program focused on IGF-1 biology.
- LOY-003: a daily pill program for large and giant dogs.
- Rapamycin: a different drug being studied in dogs through the Dog Aging Project’s TRIAD trial.
- Supplements: non-prescription products that do not have the same FDA veterinary drug review pathway.
The important owner takeaway: LOY-002 is a prescription drug candidate, not a supplement category.
Which Dogs Might Be Eligible?
Loyal’s veterinary materials describe LOY-002 as intended for dogs:
- age 10 or older
- weighing at least 14 lb
- under veterinary supervision
The final label will matter more than early public descriptions. If conditional approval happens, the label should define age, weight, health status, contraindications, monitoring, and allowed claims.
Owners should not assume LOY-002 is for every senior dog. A 10-year-old toy breed, a 10-year-old Great Dane, and a 10-year-old dog with kidney disease may have very different risk-benefit profiles.
Safety and Side Effects: What Is Known
Loyal says the FDA accepted the TAS package for LOY-002 in January 2026. Loyal’s public update says the safety package included standard dose-multiple safety testing and field safety data from more than 400 dogs that received LOY-002 for varying durations.
That is meaningful, but it is not the same as saying every rare side effect is known. Preventive drugs have a high safety bar because they may be given to generally stable dogs before severe disease develops.
When LOY-002 becomes available, the owner decision should focus on:
- whether your dog matches the label
- whether baseline bloodwork and medication review are appropriate
- what adverse events should trigger a stop or recheck
- how often your veterinarian wants monitoring
- how the drug fits alongside existing conditions such as arthritis, heart disease, kidney disease, or cognitive decline
Cost and Availability
Pricing has not been announced. Insurance coverage, pharmacy access, monitoring cost, and refill cadence are also unknown.
Assume cost will include more than the pill itself:
- initial veterinary eligibility visit
- baseline labs if your veterinarian recommends them
- prescription and refill visits
- follow-up monitoring
- management of any side effects or interactions
When pricing is announced, evaluate it against the expected absolute benefit for your dog, not against headline excitement.
Questions to Ask Your Veterinarian
Bring these questions when LOY-002 becomes available or when Loyal announces the final label:
- Does my dog match the age, weight, and health criteria?
- What benefit would be realistic for a dog like mine?
- Which conditions or medications make this riskier?
- What baseline tests should we run first?
- What monitoring schedule would you use?
- What side effects should make me stop and call you?
- Which proven longevity basics should we optimize before starting a drug?
The last question matters. For many senior dogs, lean body condition, pain control, dental disease management, mobility preservation, and earlier screening may produce more immediate benefit than waiting for a drug launch.
What to Do While Waiting
Do not leave your dog’s current health plan on pause while LOY-002 moves through review.
The strongest near-term owner actions are:
- keep body condition lean and stable
- maintain muscle with age-appropriate exercise
- use a senior screening cadence instead of symptom-only vet visits
- treat dental disease early
- track appetite, weight, mobility, sleep, and recovery trends at home
- discuss pain, cognition, and heart/kidney screening before crisis signs appear
Start with senior dog screening, weight management, dental disease and longevity, and canine frailty signals.
LOY-002 vs LOY-001
Owners often mix up Loyal’s programs.
| Program | Main target | Publicly described form | Owner question |
|---|---|---|---|
| LOY-002 | Senior dogs | Daily pill | Is my older dog eligible, and what does the final label require? |
| LOY-001 | Large and giant dogs | Long-acting veterinarian-administered product | Is my large or giant dog in the target size and age range? |
| LOY-003 | Large and giant dogs | Daily pill | Could this become the easier large-dog option later? |
If you own a giant or large breed, read both this LOY-002 guide and the large-dog LOY-001/LOY-003 pipeline section. For breed-level planning, start with canine size and lifespan biology.
Bottom Line
LOY-002 is the closest Loyal program to a potential senior-dog prescription longevity drug, but it is not approved or available yet. The FDA milestone progress is real: RXE and TAS have been accepted, while manufacturing/CMC remains the major public hurdle before conditional approval.
The best owner strategy is to track official updates, prepare smart vet questions, and keep proven longevity basics tight now. If LOY-002 reaches market, the decision should be made through the final label and your veterinarian’s risk-benefit review, not through headlines.
Frequently Asked Questions
Is LOY-002 approved? No. As of May 25, 2026, Loyal has reported RXE and TAS acceptance, but LOY-002 is not yet conditionally approved or available.
Can my veterinarian prescribe LOY-002 now? No. It cannot be prescribed until FDA grants approval and the product is commercially available through veterinary channels.
What dogs is LOY-002 for? Loyal describes LOY-002 as intended for senior dogs age 10 or older and at least 14 lb, but the final label should be treated as the operating source.
Is LOY-002 the same as LOY-001? No. LOY-002 is the senior dog program. LOY-001 and LOY-003 are large and giant dog programs focused on IGF-1-related size-lifespan biology.
What should I do while waiting for approval? Optimize the fundamentals that already have practical evidence: lean body condition, mobility, senior screening, dental care, pain management, and chronic disease monitoring.